The company grew 20% in 1Q23 due to improving procedure volumes, competitive rep recruiting and robotic pull-through.
According to our estimates, the global orthopedic market exceeded $55 billion in sales in 2022, driven by procedure volume improvement.
New technologies, increasing cementless adoption and volume-based procurement in China set the stage for a dynamic year in joint replacement.
Today we released our public and private orthopedic company sales estimates along with Joint Replacement, Spine, Trauma, Sports Medicine, Orthobiologics and Enabling Technology market projections in the latest installment of THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT.
The company grew in the low single digits for its 2023 fiscal year, but its expansive technology ecosystem is a significant advantage.
The grant will help complete pre-clinical development and testing of a synthetic total meniscus replacement in preparation for the clinic.
The financing will fund commercial growth, clinical research, and expansion of Artelon’s product line for surgical treatment of ankles and other joints.
The company’s 1Q23 orthopedic sales declined slightly as Bioventus embarks upon a quarters-long turnaround.
Monogram Orthopaedics commenced trading on NASDAQ under the ticker symbol MGRM.
The company grew its orthopedic business 9% in 1Q23, driven by favorable order timing and contributions from new products.
The company grew over 45% in 1Q23 as it further penetrates the large, underserved bunion surgical procedure market.
The company grew 26% in 1Q23 against strong comps than most of the orthopedic industry, but opted to not increase it revenue guidance.
The company grew 11.1% on a pro forma basis in 1Q23, driven by strength across its businesses and no major dissyngeries from the merge
The company grew more than 30% in the first quarter of 2023 despite ongoing staffing challenges at pediatric hospitals.
The company grew 20% in 1Q23 due to improving procedure volumes, competitive rep recruiting and robotic pull-through.
The company’s 1Q23 sales declined in the high teens as its business model shift and operational challenges take a toll.
The company grew in the high teens in 1Q23 due to easing market pressures in the U.S. and some international markets in “overdrive.”
The company grew 54% in 1Q23 and acquired the REMI navigated robotics system as ATEC prepares for the modernization of spine surgery.
Login
Register for a free account
As a guest member you get access to more articles and webinars every month.